Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
Axon 5051 - Cell signaling and Oncology Library.xls | |
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
1620 | WZ 811 | CXCR4 antagonist | €80.00 | |
2424 | WAY 100635 maleate | 5-HT1A antagonist with D4 agonistic properties | €125.00 | |
2163 | UNC669 | Antagonist of KMe reader protein L3MBTL1 and 3 | €70.00 | |
1994 | UNC1215 | Antagonist of L3MBTL3 methyllysine reader domain | €85.00 | |
2993 | UNBS5162 | Pan-antagonist of CXCL chemokine expression | €95.00 | |
3966 | TM30089 sodium | Selective CRTH2 antagonist | Inquire | |
1913 | Timapiprant | Selective DP2 (CRTH2) antagonist | €90.00 | |
1270 | T 98475 | GnRH or LHRH antagonist | Inquire | |
3058 | STING inhibitor C-178 | Highly potent and selective STING antagonist | €90.00 | |
2923 | STING inhibitor C-176 | Highly potent and selective STING antagonist | €90.00 | |
1865 | Stemregenin 1 | Aryl hydrocarbon receptor (AHR) antagonist | €105.00 | |
2807 | SPA70 | Potent and selective human pregnane X receptor (hPXR) antagonist | €125.00 | |
1447 | Seratrodast | Thromboxane A2 antagonist | €85.00 | |
1387 | SD 208 | TGF-βR 1 inhibitor | €50.00 | |
1275 | SCH 79797 dihydrochloride | PAR1 antagonist | €130.00 | |
1755 | SCH 530348 | PAR1 antagonist | €160.00 | |
2192 | SB 674042 | Nonpeptide OX1 selective antagonist with >100 fold selectivity over the OX2 receptor. | €99.00 | |
2285 | SB 525334 | Potent and selective inhibitor of the TGF-βR1 (ALK5) receptor | €105.00 | |
2197 | SB 505124 | Selective inhibitor of TGF-β type I receptors ALK4 and ALK5 | €95.00 | |
1661 | SB 431542 | TGF-βR1 inhibitor; ALK inhibitor | €70.00 | |
2095 | SB 334867 | First selective orexin 1 (OX1) antagonist | €90.00 | |
2593 | SB 332235 | Nonpeptide CXCR2 antagonist exhibiting significant anti-inflammatory effects | €105.00 | |
2183 | SB 269970 hydrochloride | Potent and selective 5-HT7 antagonist | €130.00 | |
1559 | SB 265610 | CXCR2 antagonist | €120.00 | |
1605 | S 5751 | PGD2 receptor DP1 antagonist | €115.00 | |
1680 | RU 58841 | Androgen receptor (AR) antagonist | €80.00 | |
4035 | RG-7388 | Potent and selective MDM2 antagonist | Inquire | |
1532 | RD 162 | Androgen receptor (AR) antagonist | €125.00 | |
2902 | QX77 | Chaperone-mediated autophagy (CMA) activator | €120.00 | |
2620 | Quininib | Antagonist of the cysteinyl leukotriene receptor (CysLT1 and -2) | €95.00 |